Valneva Securities Fraud Investigation
Analysis based on 7 articles · First reported Apr 02, 2026 · Last updated Apr 21, 2026
The market is negatively impacted by the significant drop in Valneva SE's stock price, reflecting investor concern over the failed clinical trial and potential securities fraud. This event highlights the inherent risks in pharmaceutical development and can lead to increased scrutiny of similar biotechnology companies.
Pomerantz LLP is investigating Valneva SE for securities fraud and other unlawful business practices. This investigation follows a substantial drop in Valneva SE's stock price on March 23, 2026, after Valneva SE and Pfizer Inc. announced that their Lyme disease vaccine candidate, PF-07307405, failed to meet its primary endpoint in the Phase 3 VALOR clinical trial. Despite the companies characterizing the data as positive, the vaccine's failure to meet its primary endpoint due to a low incidence of disease cases led to Valneva SE's American Depositary Receipt (ADR) price falling by 37.11%. Pomerantz LLP is now advising investors to contact them regarding a potential class action lawsuit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard